Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

TeamSTEPPS® : An evidence-based approach to reduce clinical errors threatening safety in outpatient settings: An integrative review.

Parker AL, Forsythe LL, Kohlmorgen IK.

J Healthc Risk Manag. 2018 Sep 13. doi: 10.1002/jhrm.21352. [Epub ahead of print]

PMID:
30212604
2.

β-tubulin carboxy-terminal tails exhibit isotype-specific effects on microtubule dynamics in human gene-edited cells.

Parker AL, Teo WS, Pandzic E, Vicente JJ, McCarroll JA, Wordeman L, Kavallaris M.

Life Sci Alliance. 2018;1(2). pii: e201800059. doi: 10.26508/lsa.201800059. Epub 2018 Apr 19.

3.

Trends and birth outcomes in adolescent refugees and migrants on the Thailand-Myanmar border, 1986-2016: an observational study.

Parker AL, Parker DM, Zan BN, Min AM, Gilder ME, Ringringulu M, Win E, Wiladphaingern J, Charunwatthana P, Nosten F, Lee SJ, McGready R.

Wellcome Open Res. 2018 May 21;3:62. doi: 10.12688/wellcomeopenres.14613.1. eCollection 2018.

4.

Designer Oncolytic Adenovirus: Coming of Age.

Baker AT, Aguirre-Hernández C, Halldén G, Parker AL.

Cancers (Basel). 2018 Jun 14;10(6). pii: E201. doi: 10.3390/cancers10060201. Review.

5.

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL.

Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29.

6.

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL.

Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24.

PMID:
29798908
7.

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.

Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G.

Mol Cancer Ther. 2018 Feb;17(2):575-587. doi: 10.1158/1535-7163.MCT-17-0671.

PMID:
29367266
8.

Practical Considerations before Installing Ground-Based Geodetic Infrastructure for Integrated InSAR and cGNSS Monitoring of Vertical Land Motion.

Parker AL, Featherstone WE, Penna NT, Filmer MS, Garthwaite MC.

Sensors (Basel). 2017 Jul 31;17(8). pii: E1753. doi: 10.3390/s17081753.

9.

An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance.

Parker AL, Teo WS, McCarroll JA, Kavallaris M.

Int J Mol Sci. 2017 Jul 4;18(7). pii: E1434. doi: 10.3390/ijms18071434. Review.

10.

A Rare Intramedullary Spinal Cord Metastasis from a Retroperitoneal Leiomyosarcoma Presenting as a Non-Traumatic Spinal Cord Injury.

Parker AL, Pugh T, Hirsch MA.

Am J Phys Med Rehabil. 2017 Jul;96(7):e134-e137. doi: 10.1097/PHM.0000000000000651.

PMID:
28628542
11.

Superlensing microscope objective lens.

Yan B, Wang Z, Parker AL, Lai YK, John Thomas P, Yue L, Monks JN.

Appl Opt. 2017 Apr 10;56(11):3142-3147. doi: 10.1364/AO.56.003142.

PMID:
28414373
12.

Empirical lessons regarding contraception in a protracted refugee setting: A descriptive study from Maela camp on the Thai-Myanmar border 1996 - 2015.

Srikanok S, Parker DM, Parker AL, Lee T, Min AM, Ontuwong P, Oo Tan S, Sirinonthachai S, McGready R.

PLoS One. 2017 Feb 23;12(2):e0172007. doi: 10.1371/journal.pone.0172007. eCollection 2017.

13.

Predictive modeling for hot water inactivation of planktonic and biofilm-associated Sphingomonas parapaucimobilis to support hot water sanitization programs.

Kaatz Wahlen L, Parker A, Walker D, Pasmore M, Sturman P.

Biofouling. 2016 Aug;32(7):751-61. doi: 10.1080/08927014.2016.1192155.

PMID:
27319816
14.

Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.

Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL.

Cancer Gene Ther. 2016 Jul;23(7):229-34. doi: 10.1038/cgt.2016.22. Epub 2016 May 27.

15.

βIII-Tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells.

Parker AL, Turner N, McCarroll JA, Kavallaris M.

Carcinogenesis. 2016 Aug;37(8):787-798. doi: 10.1093/carcin/bgw058. Epub 2016 May 4.

PMID:
27207668
16.

Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop.

Robertson S, Parker AL, Clarke C, Duffy MR, Alba R, Nicklin SA, Baker AH.

J Gen Virol. 2016 Aug;97(8):1911-6. doi: 10.1099/jgv.0.000505. Epub 2016 May 16.

17.

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL.

Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545.

18.

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL.

Viruses. 2015 Nov 24;7(11):6009-42. doi: 10.3390/v7112923. Review.

19.

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL.

Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015.

20.

Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector.

Dakin RS, Parker AL, Delles C, Nicklin SA, Baker AH.

Hum Gene Ther. 2015 May;26(5):312-9. doi: 10.1089/hum.2015.019. Epub 2015 Apr 2.

21.

Evidence for contribution of CD4+ CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery.

Nivsarkar MS, Buckley SM, Parker AL, Perocheau D, McKay TR, Rahim AA, Howe SJ, Waddington SN.

J Immunol Res. 2015;2015:397879. doi: 10.1155/2015/397879. Epub 2015 Jan 31.

22.

Fixed food eruption caused by peanut and cashew: A case report and review of the literature.

Parker AL, Pinson ML, Wohltmann WE, Gomez R.

J Allergy Clin Immunol Pract. 2015 Jan-Feb;3(1):119-22. doi: 10.1016/j.jaip.2014.08.004. Epub 2014 Oct 11. Review. No abstract available.

PMID:
25577633
23.

TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer.

McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH, Shum MS, Byrne FL, Kavallaris M.

Cancer Res. 2015 Jan 15;75(2):415-25. doi: 10.1158/0008-5472.CAN-14-2740. Epub 2014 Nov 20.

24.

Imported fire ant rush desensitization using omalizumab and a premedication regimen.

Tille KS, Parker AL.

Ann Allergy Asthma Immunol. 2014 Nov;113(5):574-6. doi: 10.1016/j.anai.2014.08.007. Epub 2014 Sep 10. No abstract available.

PMID:
25216971
25.

Microtubules and their role in cellular stress in cancer.

Parker AL, Kavallaris M, McCarroll JA.

Front Oncol. 2014 Jun 18;4:153. doi: 10.3389/fonc.2014.00153. eCollection 2014. Review.

26.

Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

Coughlan L, Uusi-Kerttula H, Ma J, Degg BP, Parker AL, Baker AH.

Hum Gene Ther. 2014 Apr;25(4):385-94. doi: 10.1089/hum.2014.016. Epub 2014 Apr 11.

PMID:
24617540
27.

Bisphenol A affects larval growth and advances the onset of metamorphosis in Drosophila melanogaster.

Weiner AK, Ramirez A, Zintel T, Rose RW, Wolff E, Parker AL, Bennett K, Johndreau K, Rachfalski C, Zhou J, Smith ST.

Ecotoxicol Environ Saf. 2014 Mar;101:7-13. doi: 10.1016/j.ecoenv.2013.12.008. Epub 2014 Jan 7.

PMID:
24507120
28.

Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.

Nee R, Parker AL, Little DJ, Yuan CM, Himmelfarb J, Lowe SR, Abbott KC.

Clin Nephrol. 2014 Jan;81(1):38-51. doi: 10.5414/CN108100.

PMID:
24161074
29.

Capsid modification strategies for detargeting adenoviral vectors.

Parker AL, Bradshaw AC, Alba R, Nicklin SA, Baker AH.

Methods Mol Biol. 2014;1089:45-59. doi: 10.1007/978-1-62703-679-5_3.

PMID:
24132476
30.

Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction.

Parker AL, White KM, Lavery CA, Custers J, Waddington SN, Baker AH.

Gene Ther. 2013 Dec;20(12):1158-64. doi: 10.1038/gt.2013.44. Epub 2013 Sep 5.

31.

Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile.

White KM, Alba R, Parker AL, Wright AF, Bradshaw AC, Delles C, McDonald RA, Baker AH.

J Cardiothorac Surg. 2013 Aug 9;8:183. doi: 10.1186/1749-8090-8-183.

32.

Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach.

Duffy MR, Parker AL, Kalkman ER, White K, Kovalskyy D, Kelly SM, Baker AH.

J Control Release. 2013 Aug 28;170(1):132-40. doi: 10.1016/j.jconrel.2013.05.007. Epub 2013 May 20.

33.

Cost-effective and scalable DNA extraction method from dried blood spots.

Saavedra-Matiz CA, Isabelle JT, Biski CK, Duva SJ, Sweeney ML, Parker AL, Young AJ, Diantonio LL, Krein LM, Nichols MJ, Caggana M.

Clin Chem. 2013 Jul;59(7):1045-51. doi: 10.1373/clinchem.2012.198945. Epub 2013 Mar 18.

34.

Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery.

Coughlan L, Bradshaw AC, Parker AL, Robinson H, White K, Custers J, Goudsmit J, Van Roijen N, Barouch DH, Nicklin SA, Baker AH.

Mol Ther. 2012 Dec;20(12):2268-81. doi: 10.1038/mt.2012.162. Epub 2012 Aug 28.

35.

Manipulation of adenovirus interactions with host factors for gene therapy applications.

Duffy MR, Parker AL, Bradshaw AC, Baker AH.

Nanomedicine (Lond). 2012 Feb;7(2):271-88. doi: 10.2217/nnm.11.186. Review.

PMID:
22339136
36.

Evaluator agreement in placement recommendations for insanity acquittees.

Stredny RV, Parker AL, Dibble AE.

Behav Sci Law. 2012 May-Jun;30(3):297-307. doi: 10.1002/bsl.1995. Epub 2012 Jan 9.

PMID:
22231548
37.

Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA, Baker AH.

Viruses. 2010 Oct;2(10):2290-355. doi: 10.3390/v2102290. Epub 2010 Oct 13.

38.

A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes.

Duffy MR, Bradshaw AC, Parker AL, McVey JH, Baker AH.

J Virol. 2011 Oct;85(20):10914-9. doi: 10.1128/JVI.05382-11. Epub 2011 Aug 17.

39.

COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78.

Kitahara H, Masumoto J, Parker AL, Maruta F, Kubo N, Shimizu A, Akita N, Miwa S, Kobayashi N, Nakayama J, Miyagawa S.

Mol Cancer Res. 2011 Jun;9(6):688-701. doi: 10.1158/1541-7786.MCR-10-0470. Epub 2011 May 13.

40.

Development of a metabolic equation for the NuStep recumbent stepper in older adults.

Dalleck LC, Borresen EC, Parker AL, Abel KM, Habermann LA, McLaughlin SJ, Tischendorf JS.

Percept Mot Skills. 2011 Feb;112(1):183-92.

PMID:
21466091
41.

Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Bradshaw AC, Parker AL, Duffy MR, Coughlan L, van Rooijen N, Kähäri VM, Nicklin SA, Baker AH.

PLoS Pathog. 2010 Oct 7;6(10):e1001142. doi: 10.1371/journal.ppat.1001142.

42.

Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.

Othman M, Chirinian Y, Brown C, Notley C, Hickson N, Hampshire D, Buckley S, Waddington S, Parker AL, Baker A, James P, Lillicrap D.

Blood. 2010 Nov 4;116(18):3645-52. doi: 10.1182/blood-2009-12-261131. Epub 2010 Aug 9.

43.

Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, Waddington SN, Buckley SM, Greig JA, Parker AL, Miller AM, Wang H, Lieber A, van Rooijen N, McVey JH, Nicklin SA, Baker AH.

Blood. 2010 Oct 14;116(15):2656-64. doi: 10.1182/blood-2009-12-260026. Epub 2010 Jul 7.

44.

Self-assembly of peptides into spherical nanoparticles for delivery of hydrophilic moieties to the cytosol.

Collins L, Parker AL, Gehman JD, Eckley L, Perugini MA, Separovic F, Fabre JW.

ACS Nano. 2010 May 25;4(5):2856-64. doi: 10.1021/nn901414q.

PMID:
20408581
45.

Multisensory congruency as a mechanism for attentional control over perceptual selection.

van Ee R, van Boxtel JJ, Parker AL, Alais D.

J Neurosci. 2009 Sep 16;29(37):11641-9. doi: 10.1523/JNEUROSCI.0873-09.2009.

46.

Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.

Greig JA, Buckley SM, Waddington SN, Parker AL, Bhella D, Pink R, Rahim AA, Morita T, Nicklin SA, McVey JH, Baker AH.

Mol Ther. 2009 Oct;17(10):1683-91. doi: 10.1038/mt.2009.152. Epub 2009 Jul 14. Erratum in: Mol Ther. 2009 Oct;17(10):1830.

47.

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH, Baker AH.

Blood. 2009 Jul 30;114(5):965-71. doi: 10.1182/blood-2009-03-208835. Epub 2009 May 8.

48.

Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer.

Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N, Goudsmit J, McVey JH, Nicklin SA, Baker AH.

J Virol. 2009 Jan;83(1):479-83. doi: 10.1128/JVI.01878-08. Epub 2008 Oct 22.

49.

Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications.

Parker AL, Nicklin SA, Baker AH.

Curr Opin Mol Ther. 2008 Oct;10(5):439-48. Review.

PMID:
18830919
50.

Successful administration of a 1-day imported fire ant rush immunotherapy protocol.

Judd CA, Parker AL, Meier EA, Tankersley MS.

Ann Allergy Asthma Immunol. 2008 Sep;101(3):311-5. doi: 10.1016/S1081-1206(10)60497-8.

PMID:
18814455

Supplemental Content

Loading ...
Support Center